Suppr超能文献

维拉帕米对人慢性粒细胞白血病细胞米托蒽醌细胞毒性的调节作用。

Modulation of mitoxantrone cytotoxicity by verapamil in human chronic myeloid leukemia cells.

作者信息

Satyamoorthy K, Chitnis M P, Pradhan S G, Advani S H

机构信息

Cellular Chemotherapy Unit, Tata Memorial Hospital, Tata Memorial Center, Parel, Bombay, India.

出版信息

Oncology. 1989;46(2):128-31. doi: 10.1159/000226699.

Abstract

Calcium channel-blocking agent verapamil has been established to be an effective drug to modulate the action of many anticancer drugs. In this study, we examined the effect of verapamil on the cytotoxicity of mitoxantrone in human chronic myeloid leukemia (CML) cells. Mitoxantrone alone exhibited dose-dependent inhibition of DNA biosynthesis in CML cells. The addition of verapamil (3.3 microM) enhanced the responsiveness of CML cells to mitoxantrone (1 microgram/ml) cytotoxicity indicated by significant increased inhibition of thymidine incorporation (p less than 0.001). The present study demonstrates the possible efficacy of verapamil in the chemotherapy of CML with mitoxantrone.

摘要

钙通道阻滞剂维拉帕米已被证实是一种可调节多种抗癌药物作用的有效药物。在本研究中,我们检测了维拉帕米对米托蒽醌在人慢性粒细胞白血病(CML)细胞中的细胞毒性的影响。单独使用米托蒽醌对CML细胞的DNA生物合成表现出剂量依赖性抑制作用。加入维拉帕米(3.3微摩尔)增强了CML细胞对米托蒽醌(1微克/毫升)细胞毒性的反应性,表现为胸苷掺入的抑制显著增加(p小于0.001)。本研究证明了维拉帕米在米托蒽醌治疗CML化疗中的可能疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验